In this free webinar, learn how spatial immunophenotyping assays are being used to understand the whole tumor microenvironment in patient biopsy samples. Attendees will learn how multiplex immunofluorescence (mIF) assays can reveal the spatial relationships between tumour cells, engineered T-cells, endogenous T-cells, other immune cells and stromal components in tumour cells. The featured speakers will also explore how advanced spatial metrics analysis tools help in studying cellular spatial patterns within the tumour tissue, including the utilization of imaging software for analyzing subsets of immune cells.
TORONTO, June 11, 2024 /PRNewswire-PRWeb/ -- Patient biopsy samples received from Adaptimmune's clinical trials are considered very precious, therefore careful consideration is taken to decide which histological staining and assays are used on these tissue sections. These analyses serve to achieve our team and research department's primary endpoints as well as help determine which assays can provide the clearest understanding of the whole tumour microenvironment (TME).
Multiplex immunofluorescence (mIF) assays, like Ultivue's 8-plex panels, offer the advantage of preserving the architectural features of the tumour microenvironment (TME) by utilising a single tissue section for multi-target profiling. This can reveal the spatial relationships between tumour cells, Adaptimmune engineered T-cells, endogenous T-cells, other immune cells, and stromal components that are present.
In this webinar, we will introduce how we use these Ultivue panels alongside conventional H&E, IHC, and our other in-house assays. In addition, we will show examples of pre- and post-treatment patient biopsies for multiple indications to demonstrate how we utilize image analysis software to quantify cell densities of subsets of infiltrating immune cells. We will also describe how we use the spatial analysis tools to study cellular spatial patterns within the tumour tissue, and how these are used to understand the effectiveness and mechanism of our cell-based therapies.
Register for this webinar today to learn how multiplex immunofluorescence panels help determine the effectiveness of cell therapies for solid tumors.
Join experts from Adaptimmune, Dr. Martin Isabelle, Associate Director, Tumour Profiling, Translational Sciences Group; and Dr. Robyn Broad, Principal Scientist, Tumour Profiling, Translational Sciences Group, for the live webinar on Monday, June 24, 2024, at 10am EDT (3pm BST/UK).
For more information, or to register for this event, visit Investigating Cell Therapy Efficacy Mechanisms in Solid Tumors by Spatial Immunophenotyping.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Soumya Shashikumar, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com/
SOURCE Xtalks
Share this article